Tessara Therapeutics partners with CCRM Australia and joins the Centre for Commercialization of Regenerative Medicine’s Industry Consortium

The Centre for Commercialization of Regenerative Medicine Australia (CCRM) Australia is proud to partner with Tessara Therapeutics.  This will introduce the company to a growing international consortium of over 100 companies within the CCRM industry consortium.

 

Tessara Therapeutics will now enjoy benefits extended to all CCRM industry consortium members to assist with development and growth, including regular sector updates and insights. Membership of the industry consortium also provides opportunities to connect with other relevant partner companies directly, both at a local and international level.

 

CCRM Australia’s CEO, Silvio Tiziani, noted, “We are delighted that Tessara Therapeutics has agreed to partner with CCRM Australia and join our growing industry consortium.  Tessara is an active participant in the rapidly expanding Australian regenerative medicine sector and aims to commercialise its proprietary RealBrain® platform for high-throughput drug screening and regenerative medicine applications for neurological diseases. Through CCRM’s connections, we will be able to support Tessara’s business aspirations and development of its unique neural micro-tissue technology”.

 

Established to promote and support Australia’s regenerative medicine sector, CCRM Australia’s ability to create opportunities for Tessara through its international consortia is just one way CCRM Australia can bring value to Australian companies and researchers.

 

Dr Christos Papadimitriou, Tessara Therapeutics’ CEO commented, “Tessara is pleased to partner with CCRM Australia. We see this partnership as a great opportunity to showcase our RealBrain® technology and connect with CCRM’s valuable worldwide network of researchers, academic institutions and industry partners in the field of regenerative medicine. As we develop and commercialise our RealBrain® drug screening and regenerative medicine platforms, we are interested to explore collaborations in which the physiological relevance and reproducibility of our neural micro-tissues can be leveraged to accelerate the development of effective treatments for many brain diseases”.

 

About CCRM Australia

CCRM Australia is an Australian not-for-profit organisation supporting the development of foundational technologies to accelerate the commercialisation of regenerative medicine products and therapies. CCRM Australia’s focus is to bridge the commercialisation gap through a network of scientists, entrepreneurs, academic institutions and industry partners and address bottlenecks in the industry. CCRM Australia is modelled on the highly successful CCRM in Canada and is legally separate to CCRM. As a Global CCRM network member, CCRM Australia is a partner to a leading-edge industry consortium. MTPConnect and the Victorian State Government support CCRM Australia.

 

About Tessara Therapeutics

Tessara Therapeutics is developing RealBrain® technology to break therapeutic barriers in the biopharmaceutical industry. RealBrain® human mimetic 3D neural micro-tissues are designed with high physiological relevance, and manufactured at industrial scale for unprecedented reproducibility. Priority applications include a high-throughput drug screening platform based on innovative 3D models of human brain tissue in healthy and disease states, and a regenerative medicine platform to develop next generation, safe and efficacious tissue replacement therapies for significant unmet medical needs of patients suffering from neurological diseases. www.tessaratherapeutics.com

 

For more information, please contact:

 

CCRM Australia:

Dr Chih Wei Teng

Chief Operations Officer

+61 (0)3 9902 9603

chihwei.teng@ccrmaustralia.com.au

www.ccrmaustralia.com.au

 

Tessara Therapeutics:

Christopher Boyer

Chief Business Officer

+61 401 240 260

christopher.b@tessaratx.com

www.tessaratherapeutics.com